2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseases
- 7 June 2020
- journal article
- research article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 52 (2), 276-283
- https://doi.org/10.1111/apt.15804
Abstract
Background Data on patients with inflammatory bowel diseases (IBD) who have had 2019 novel coronavirus (SARS‐CoV‐2) disease (COVID‐19) are lacking. Aim To report the clinical characteristics, including gastrointestinal symptoms, of COVID‐19 in IBD patients, and to assess the risk of COVID‐19 in IBD. Methods This case series included consecutive IBD patients with laboratory‐confirmed COVID‐19. Age‐adjusted cumulative incidences were compared with the general population in the Madrid region. Results Through April 8, 12 patients of 1918 IBD patients were diagnosed of COVID‐19. The average age was 52 years, 75% of the patients were female, and 58.3% had Crohn’s disease. Seven patients (58%) were on maintenance treatment with immunomodulators/biologics, of these 4 with combined therapy (33%). Eight patients (66%) required hospitalization (1 intensive care unit admission, and 2 deaths), and 4 patients were isolated at home. Nine patients had diarrhoea ranging between 4‐10 loose stools per day (mean 5.4, SD 1.6). In 5 patients (42%) diarrhoea was a presenting symptom. In 2 patients, diarrhoea was the only symptom at debut. Cumulative incidence of COVID‐19 was 6.1 per 1000 IBD patients. IBD patients had a lower adjusted incidence ratio of COVID‐19 (OR 0.74, 95% CI 0.70‐0.77; p<0.001), and a similar associated mortality ratio (OR 0.95, 95% CI: 0.84‐1.06; p=0.36), compared with the general population. Conclusions IBD patients do not have an increased risk of COVID‐19 and associated mortality compared with the general population. In many IBD patients diarrhoea was a presenting symptom, and sometimes, was the only symptom at onset of COVID‐19.Keywords
This publication has 36 references indexed in Scilit:
- Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS CoronavirusJournal of Virology, 2020
- Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus EntryJournal of Virology, 2020
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurinesUnited European Gastroenterology Journal, 2019
- Imbalance of the renin–angiotensin system may contribute to inflammation and fibrosis in IBD: a novel therapeutic target?Gut, 2019
- Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel DiseaseBioMed Research International, 2019
- Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirusScience Advances, 2017
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled TrialsThe American Journal of Gastroenterology, 2013
- Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumoniaCritical Care, 2011
- Viral Loads in Clinical Specimens and SARS ManifestationsEmerging Infectious Diseases, 2004